...
0,00  0

Basket

Žiadne produkty v košíku.

No products in the basket.

Continue shopping

Carnosine and depression

Combination treatment with L-carnosine for major depressive disorderkarnozín a depresia

Randomized, double-blind, placebo-controlled study

Prof. Alan Hipkis – English scientist and professor at Aston University, Birmingham, has conducted extensive research on the therapeutic effects of carnosine. In. 2015, he published a study showing that carnosine has great potential in the treatment of depression due to its anti-stress effects, support of cortisol metabolism and ability to preserve the length of telomeres (the terminal portion of eukaryotic chromosomes). (1)

Based on his research, he concluded that when carnosine is administered as a dietary supplement, it is capable of positively influencing behavior in people suffering from depression. This supported the idea that there is a need to investigate the therapeutic potential of carnosine in the treatment of depression and post-traumatic stress disorder.

Due to the finding that carnosine affects the glutamate system (1, 2), a study was published in 2020 in the Journal of Affective Disorders (Impact Factor: 3.892) focusing on the use of carnosine as a supportive therapy in the treatment of major depressive disorder (3). The study was conducted in such a way that 58 patients with MDD (DSM- V) and Hamilton Depression Rating Scale (HAM- D) scores ≥ 19 were randomly selected to receive either 400 mg twicet daily L-carnosine or placebo in addition to citalopram (maximum dose 40 mg/day) for six weeks in a randomized double-blind, placebo-controlled trial.

In this study, we sought to evaluate the efficacy and tolerability of combination therapy with L-carnosine in the treatment of patients with major depressive disorder (MDD). Patients were assessed using the HAM-D scale at baseline and 2, 4. The safety and efficacy of L-carnosine were evaluated on depressive symptoms in patients with major depressive disorder and L-carnosine treatment appears to be well tolerated without serious adverse event.

The results are very promising!

1. There was a statistically significant improvement in the carnosine group – patients were more responsive to treatment and a higher remission rate (improvement in illness) was achieved

2. the HDRS score improved significantly in the carnosine group at each assessment – after 2, 4, 6 weeks

Effects were assessed using the Hamilton Depression Rating Scale (HDRS), which is the most commonly used scale to assess the severity of depressive symptoms (depressed mood, guilt, suicidal intentions, somatic anxiety, insomnia, somatic gastrointestinal symptoms, retardation, psychological distress, genital symptoms, hypochondria, weight loss, restlessness, withdrawal).

[div : well]

Given the current pandemic situation, fraught with uncertainty and tension, it is more than certain that people’s mental health will suffer globally. We believe that this kind of nutritional supplement can also make a difference to our well-being and mental health.

[div]

Information Source:

https:// www.ncbi.nlm.nih.gov/pmc/articles/PMC4567213/
https:// pubmed.ncbi.nlm.nih.gov/27040711/
https:// pubmed.ncbi.nlm.nih.gov/32063564/
https://bmjopen.bmj.com/content/10/9/e040620.abstract

L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial – ScienceDirect

References:

(1) Hipkiss, A.R., 2015. Possible benefit of dietary carnosine towards depressive disorders. Aging and disease, 6(5), p.300._
(2) Ouyang, L., Tian, Y., Bao, Y., Xu, H., Cheng, J., Wang, B., Shen,Y., Chen, Z. and Lyu, J., 2016. Carnosine decreased neuronal cell death through targeting glutamate system and astrocyte mitochondrial bioenergetics in cultured neuron/astrocyte exposed to OGD/recovery. Brain research bulletin, 124, pp.76-84._
(3) Araminia, B., Shalbafan, M., Mortezaei, A., Shirazi, E., Ghaffari, S., Sahebolzamani, E., Mortazavi, S.H., Shariati, B., Ardebili, M.E., Aqamolaei, A. and Naderi, S., 2020. L-Carnosinecombination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial. Journal of Affective Disorders, 267, pp.131-136._
(4) Jia, R., Ayling, K., Chalder, T., Massey, A., Broadbent, E., Coupland, C. and Vedhara, K., 2020. Mental health in the UK during the COVID-19 pandemic: cross-sectional analyses from a community cohort study. BMJ open, 10(9), p.e040620.

Opening hours

Monday
09.00 - 17.00 hod.
Tuesday
09.00 - 17.00 hod.
Wednesday
09.00 - 17.00 hod.
Thursday
09.00 - 17.00 hod.
Friday
09.00 - 17.00 hod.

Our socials

Registrácia

Prihlásenie